Tempus AI (TEM) M&A announcement summary

Deal rationale and strategic fit

• Acquisition integrates advanced MRD technology into an AI-enabled oncology platform, expanding participation in the $20 billion+ MRD market with a comprehensive tumor-informed and tumor-naive testing portfolio.

• Accelerates commercial adoption and test volume growth by leveraging a larger salesforce and commercial infrastructure.

• Enriches data capabilities with proprietary longitudinal data, enhancing insights for clinicians, biopharma clients, and supporting new product development.

• Builds on an existing partnership and enables more integrated biomarker and drug development collaborations.

• The combined portfolio is positioned as highly complementary and comprehensive across cancer diagnostics and monitoring.

Financial terms and conditions

• Personalis shareholders will receive $16.25 per share, representing a 6% premium to the prior close and a 28% premium to the 30-day VWAP.

• Total transaction value is $1.7 billion ($1.5 billion net of existing ownership).

• Consideration is a mix of stock and up to 50% cash, with a floating exchange ratio capped at 0.3356.

• Cash portion can be financed with cash on hand, existing credit facilities, or new borrowing.

• Transaction is expected to close in late 2026 or early 2027, subject to approvals.

Synergies and expected cost savings

• Integration will enable broader sales force deployment and unlock higher MRD test volumes as more indications secure reimbursement.

• Combining data assets is expected to enrich biopharma offerings, support trial optimization, and advance biomarker discovery.

• Enhanced scale and resources are expected to accelerate innovation and value delivery to patients and partners.